The primary objective of the study conducted by Koczan et al. was to identify biomarkers that could predict therapeutic outcomes in RA patients treated with the tumor necrosis factor-alpha (TNF-α) blocker, etanercept. Here, TNF is linked to rheumatoid arthritis.